Obesity drug price tags could cost Saudi Arabia billions, analysis warns

Obesity has become one of the defining health challenges of our time, and nowhere is that more visible than in Saudi Arabia, where high prevalence of excess weight feeds directly into chronic disease and swelling healthcare bills. The arrival of highly effective new weight-loss injections — the glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists — has transformed what medicine can offer patients. But these drugs carry price tags to match their power, and a new analysis published in BMC Health Services Research puts hard numbers on what widespread adoption would mean for the kingdom’s payers.

Researchers Ali M. Alshahrani of Taif University and Ahmed M. Ashour of Umm Al-Qura University built a budget impact analysis to estimate the financial consequences of adopting these novel anti-obesity medications (AOMs) in Saudi Arabia over both 5-year and 10-year horizons. Rather than relying on generic international estimates, they constructed a static cohort model tailored to the Saudi context, running it separately from two very different payer perspectives: the public system under the Ministry of Health (MoH) and the private insurance sector governed by the Council of Cooperative Health Insurance (CCHI). This dual-lens approach matters because public and private payers face different populations, different negotiating power, and different procurement channels.

The technical scaffolding of the model drew on an unusually comprehensive set of country-specific data sources. Adult population figures and obesity prevalence came from GASTAT, the kingdom’s national statistics agency, and the Saudi Health Interview Survey. Prevalence of obesity-related comorbidities — conditions such as type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and non-alcoholic steatohepatitis — was sourced from Ministry of Health reports and published studies. Crucially, drug acquisition costs were not taken from list prices alone but derived from the Saudi Food and Drug Authority (SFDA) price lists and procurement data from the National Unified Procurement Company (NUPCO), the centralized purchasing body for the public sector. That grounding in real Saudi procurement economics is what separates this analysis from the many international budget estimates that circulate without local calibration.

The researchers evaluated two distinct eligibility scenarios to capture the policy choices facing decision-makers. The first extended coverage to all adults with a body mass index (BMI) of 30 kg/m² or higher, regardless of other health status. The second, more restrictive scenario limited eligibility to individuals with BMI ≥ 30 kg/m² who also carried at least one obesity-related comorbidity — the higher-risk population that most clinical guidelines prioritize. Uptake rates, adherence patterns, and discontinuation rates were informed by the landmark STEP and SURPASS clinical trial programs, then adjusted to reflect the realities of the Saudi healthcare environment rather than the idealized conditions of trial settings.

The headline numbers are striking. Under the BMI-plus-comorbidity scenario — the narrower, higher-risk eligibility — cumulative 10-year expenditure was estimated at SAR 10.96 billion for public payers and SAR 5.68 billion for private payers. That means the public system would shoulder nearly twice the burden of the private insurance sector, a reflection of the larger populations served by the Ministry of Health and the centralized NUPCO procurement channel. But when eligibility expanded to every adult with BMI ≥ 30 kg/m², the picture changed dramatically: cumulative public expenditure over 10 years climbed to SAR 18.9 billion, an increase of roughly 72 percent over the restricted scenario. The gap between those two figures is essentially the price of broadening access from the highest-risk patients to the full obese population.

Sensitivity analyses revealed which parameters drove these costs most powerfully. Two factors dominated: the uptake rate — how many eligible patients actually start and stay on the medications — and the drug acquisition cost itself. This finding has direct policy implications. Because uptake is such a powerful lever, phased introduction strategies that gradually expand the treated population can meaningfully smooth expenditure over time. And because acquisition cost matters so much, negotiation and procurement efficiency — areas where NUPCO’s centralized purchasing could prove decisive — represent another avenue for controlling the fiscal impact without restricting access outright.

What makes this analysis timely is the collision between clinical enthusiasm and fiscal reality. The STEP trials demonstrated substantial weight reduction for semaglutide, a GLP-1 receptor agonist, while the SURPASS program showed even greater efficacy for tirzepatide, the dual GIP/GLP-1 receptor agonist. These are genuinely transformative results by the standards of obesity pharmacotherapy, and they explain why demand has surged globally. But the same efficacy that makes these drugs medically compelling makes them financially formidable when applied at population scale. A single patient on long-term injectable therapy represents a recurring annual cost, and when multiplied across hundreds of thousands of eligible individuals, the arithmetic becomes sobering for any health system.

Saudi Arabia faces a particular version of this dilemma. The kingdom’s obesity prevalence is high, its chronic disease burden is substantial, and its Vision 2030 reform agenda includes explicit commitments to improving population health. Yet the same health system must also absorb the costs of these new therapies without crowding out other essential services. The authors’ conclusions point toward a pragmatic middle path: restricting reimbursement to higher-risk populations — those with comorbidities who stand to gain the most clinically — and implementing phased uptake strategies that expand eligibility gradually as fiscal capacity allows. This approach, they argue, may improve affordability while preserving access to effective obesity treatments for those who need them most.

The study has limits worth acknowledging. As a static cohort model, it projects costs without modeling dynamic changes in population health over time — it does not, for instance, estimate downstream savings from reduced cardiovascular events or diabetes complications that successful weight loss might eventually produce. Budget impact analyses are deliberately narrow instruments: they answer the question of what adoption will cost, not whether that cost is worthwhile. Cost-effectiveness analysis, which weighs costs against health gains, is a separate exercise requiring different methods and assumptions. The authors also note the analysis used aggregated publicly available secondary data rather than patient-level records, which means it relied on population averages rather than individual treatment trajectories.

Nevertheless, the analysis arrives as health systems worldwide grapple with the same question Saudi payers now face: how to reconcile the clinical revolution in obesity medicine with the budgetary constraints of real-world health financing. The Saudi estimates — SAR 10.96 billion and SAR 5.68 billion over a decade for public and private payers respectively under restricted eligibility, rising to SAR 18.9 billion publicly under broad access — offer a concrete, locally calibrated starting point for that conversation. As novel anti-obesity medications continue to demonstrate efficacy and capture global attention, country-specific budget impact analyses like this one will be essential tools for informing coverage and reimbursement decisions. For Saudi Arabia, the message is clear: these drugs can transform individual patient outcomes, but their population-level fiscal footprint will be substantial, and the choices made now about eligibility and uptake will shape healthcare expenditure for years to come.

Subject of Research: obesity-drugs-saudi-budget

Article Title: Budget impact of GLP-1 and dual GIP/GLP-1 receptor agonists for obesity management in Saudi Arabia: a budget impact analysis from public and private payer perspectives

Article References: Alshahrani, A. M., & Ashour, A. M. (2026). Budget impact of GLP-1 and dual GIP/GLP-1 receptor agonists for obesity management in Saudi Arabia: a budget impact analysis from public and private payer perspectives. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15623-7

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15623-7

Keywords: Budget, impact, GLP-1, dual, receptor, agonists, obesity, management, Saudi, Arabia, analysis, public